case_images: PMC10148232_01
case_images: Concentric visual field restrictions on a 30-2 Humphrey field analyser in (a) right eye and (b) left eye at presentation, with mean deviation of -10.08 dB (OD) and -16.46 dB (OS). The visual threshold greyscale map, numerical sensitivity plot, total deviation, and pattern deviation for each eye are shown from left to right.
case_images: cop530221_f01.jpg
case_images: PMC10148232_01_cop530221_f01.jpg
case_images: F1
case_images: Repeatable concentric visual field constriction was confirmed in both eyes on 30-2 Humphrey visual field testing at presentation (shown in Fig. 1a, b) and at 3 months' follow-up (shown in Fig. 2a, b).
case_images: Significant improvement of visual fields on a 30-2 Humphrey field analyser in (a) right eye and (b) left eye 3 months after discontinuation of therapy, with a mean deviation of -1.98 dB (OD) and -1.60 dB (OS). The visual threshold greyscale map, numerical sensitivity plot, total deviation, and pattern deviation for each eye are shown from left to right.
case_images: cop530221_f03.jpg
case_images: PMC10148232_01_cop530221_f03.jpg
case_images: F3
case_images: Three months after discontinuation of ezetimibe, there was near complete resolution of the bilateral concentric field loss and significant symptom improvements (shown in Fig. 3a, b).
case_images: Complete resolution of visual field deficits on a 30-2 Humphrey field analyser in (a) right eye and (b) left eye 12 months after discontinuation of therapy, with a mean deviation of +1.25 dB (OD) and +0.25 dB (OS). The visual threshold greyscale map, numerical sensitivity plot, total deviation, and pattern deviation for each eye are shown from left to right.
case_images: cop530221_f04.jpg
case_images: PMC10148232_01_cop530221_f04.jpg
case_images: F4
case_images: Twelve months after therapy discontinuation, visual fields returned to baseline in both eyes, and there were no new symptoms (shown in Fig. 4a, b).